



SCIENCE + SOFTWARE = SUCCESS

16th Annual Needham Technology &
Media Conference

Shawn O'Connor, CEO

May 20, 2021

Safe Harbor Statement

With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include but are not limited to: continuing demand for the Company's products, competitive factors, the Company's ability to finance future growth, the Company's ability to produce and market new products in a timely fashion, the Company's ability to continue to attract and retain skilled personnel, and the Company's ability to sustain or improve current levels of productivity. Further information on the Company's risk factors is contained in the Company's quarterly and annual reports and filed with the Securities and Exchange Commission.

Mission

Our mission is to create value for our customers by accelerating and reducing the costs of R&D through innovative science-based software and consulting solutions that optimize treatment options and improve patient lives.



Company Overview

- ❑ **Industry-leading** provider of modeling and simulation solutions used by major pharmaceutical, biotech, chemical, consumer goods companies and regulatory agencies worldwide
- ❑ Innovative **software and services** to improve drug development from discovery to regulatory approval with supportive guidance from the FDA and ability to **lower cost** and time to market with a **higher likelihood of success**
- ❑ Solutions bridge **machine learning** and include pharmacokinetic-pharmacodynamic (**PKPD**), quantitative systems pharmacology & toxicology (**QSP/QST**), and physiologically based pharmacokinetic (**PBPK**), Physiologically-Based Biopharmaceutics (**PBBM**) Modeling
- ❑ 10+ year track record of **consistent revenue and profitability** growth and successful M&A strategy

Our Value Proposition


Avg. cost of \$1.4B and 10+ years to bring a drug to market ^{1,2}

Our solutions allow customers to model and predict results of chemical and biological tests required in the R&D process to improve success rates at multiple points in the process:

- Computational AI models help scientists streamline and improve their processes
- Machine learning improves the models with ever-growing data sets
- Better informed clinical trial design and analyze clinical results
- Identify potential safety liabilities earlier, avoiding costly clinical failures
- Optimize efficacy and minimize toxicity by efficiently identifying dosing regimens

We've helped bring 40+ drugs to market and informed multiple development programs

We Improve Drug Discovery and Development



PBPK Software Solutions and AI Data Mining



GastroPlus®

Simulating IV, oral, oral cavity, ocular, inhalation, skin and IM absorption, PBPK, PBBM, PD modeling and drug-drug interactions



ADMET Predictor®

QSAR modeling enabling rapid prediction of 140+ ADMET properties Used for lead generation and optimization



DDDPlus™

Mechanistic simulation engine for the in vitro dissolution predictions to accelerate and optimize drug formulation



MembranePlus™

Predict how fast a drug candidate will pass across the important physiological membrane barriers (GI, BBB)



MedChem Designer™

Chemical sketching tool with ADMET property predictions in connection with ADMET Predictor

PKPD Software Solutions



Monolix Suite®

Population PKPD Model to support dose regimen, risk exposure, clinical trial protocol design and analysis, drug label specifications and regulatory submission

Datxplore

Exploration and visualization of data

PKanalix

Non-compartmental and compartmental analysis

MIxplore

Exploration and visualization of complex models

Monolix

Non-linear mixed effects (NME) modeling engine

Simulx

Clinical trial pharmacometrics simulations



KIWI™

Cloud-based data management application

QSP/QST Software Solutions



DILIsym™

Determine potential drug-induced liver injury hazard posed by individual drug candidates to support clinical trial optimization



RENAsym™

Assess the potential for drug-induced kidney injury of drug candidates to support clinical trial optimization and clinical trial decision making



NAFLDsym™

NASH model to predict efficacy for treatment modalities to support clinical trial optimization and clinical trial decision making



IPFsym™



RADAsym™

IPFsym (Idiopathic pulmonary fibrosis)
RADAsym (Acute radiation exposure)

Services Solutions

- 70+ scientific PhD experts provide insightful solutions to improve the productivity of science-based drug development
- Focusing on lead selection, pharmacology, ADMET and DMPK, dose regimen, efficacy and safety
- Capabilities include:
 - Population PKPD data assembly, modeling, simulation, analysis and regulatory submission
 - PBPK modeling and simulation
 - Liver and kidney safety modeling and analysis
 - QSP/QST modeling support and analysis
 - AI drug candidate prioritization
 - Global regulatory strategies
 - Regulatory and scientific writing



Janssen Case Study:

Accelerating Regulatory Interactions

Virtual crossover trials to establish drug product specification after manufacturing changes

- Janssen changed the manufacturing process to improve efficiencies with scale-up techniques post approval
- FDA requested clinical study to confirm bioequivalence
- Built and validated the baseline model in GastroPlus® using existing clinical data from previously approved lots
- Assessed impact of formulation changes; defined drug product specifications
- Performed virtual trial simulations in different populations to confirm bioequivalence
- FDA accepted the GastroPlus® modeling results, clinical study request was waived

Virtual Bioequivalence Study Simulations

API Lot	PE/NPE	Dose (mg)	AUC _∞ (ng.h/mL) (N=250)		C _{max} (ng/mL) (N=250)	
			GM	GMR (90% CI)	GM	GMR (90% CI)
Lot 5	PE	50	4180	113.3	551	139.3
Lot 1	NPE	50	3688	(110.7, 116.1)	395	(136.0, 142.7)
Lot 5	PE	100	8242	103.0	551	106.4
Lot 3	NPE	100	8001	(100.9, 105.1)	395	(104.3, 108.6)
Lot 5	PE	300	24998	102.2	3118	100.0
Lot 2	NPE	300	24460	(99.8, 104.6)	3117	(97.7, 102.4)
Lot 5	PE	100	8242	98.2	1068	95.1
Lot 4	NPE	100	8395	(96.2, 100.2)	1123	(93.2, 97.0)
Lot 5	PE	300	24998	101.9	3118	98.3
Lot 4	NPE	300	24525	(99.8, 104.1)	3171	(96.3, 100.4)

API: active pharmaceutical ingredient; AUC_∞: area under the plasma concentration-time curve from time 0 to infinite time; CI: confidence interval; C_{max}: maximum observed plasma concentration; GM: geometric mean; GMR: geometric mean ratio; NPE: non-particle-engineered; PE: particle-engineered

Client Case Study:

Strategic Use of Modeling & Simulation

In Silico Methods Improve the Probability of Phase 3 Success

- Client with novel antibody for prophylactic use in competitive migraine market had Phase 3 development plan with predicted probability of success of <15%
- Iteratively developed model throughout Phase 1 & Phase 2
- Implemented model-based clinical trial simulation strategy to improve Phase 3 design
- Phase 3 trials demonstrated safety and efficacy in preventing migraine
- Months of development time and millions of dollars saved by avoiding failed Phase 3 trials, also reduced time to approval and market
- Reduced unnecessary burden on patients by evaluating multiple alternatives *in silico* before running trials

Growth Drivers

Increasing acceptance of modeling and simulation by FDA and drug industry

High customer satisfaction with ~95% software contract renewal rate (by fees)

Recently improved and expanded sales infrastructure


Increasing opportunities for product and service cross-selling

Steadily increasing industry R&D spend

Synergistic acquisitions

19%+
Revenue
CAGR


Consistent Revenue Growth FY21 YTD (through Q2)




Software and Services Performance

FY21 YTD (through Q2)

Software Products % of Software Revenues




Services Offerings % of Services Revenues



Global Customer Base

Revenue by Region
FY21 YTD (through Q2)



Strategic Opportunities for Expansion and Growth

- Expand product offerings through opportunistic acquisitions
 - Fill gaps in the current product offerings
 - Focus on immediately or near-term accretive opportunities
 - Fragmented industry amenable to consolidation
- Further expand global sales reach
 - Increase sales effort to drive new customer growth in U.S., Europe and Asia
 - Expand client base in the small and mid-sized biotechnology space
 - Focus on cross-selling efforts to increase average revenue per customer
- Increase R&D investment to enhance existing models and develop new tools to broaden product offerings

FY21 Q2 YTD Performance & FY21 Full Year Guidance

- **Total Revenue Growth**
 - YTD performance: 21% y/y growth
 - Full-year guidance range: 15-20% y/y organic growth plus 3-5% from Lixoft
- **Software Revenue Growth**
 - YTD performance: 40% y/y growth
 - Full-year guidance range: 20-25% y/y growth
- **Services Revenue Growth**
 - YTD performance: 1% y/y growth
 - Full-year guidance range: 25-30% y/y growth
- **YTD Profitability**
 - Gross margin was 78%, up from 73% prior fiscal year
 - Net income increased 35% y/y to \$5.7 million
 - Diluted earnings per share increased 17% y/y to \$0.27
- **M&A Efforts**
 - Continuing to explore opportunities and acquisitions that would be incremental to revenue growth targets above

Investment Highlights

- ✓ Leading provider of innovative modeling and simulation software and consulting services focused on pharmaceutical and biotechnology companies
 - Solutions from early discovery through regulatory approval
- ✓ Pure play in the *in silico* drug discovery space
- ✓ Growing acceptance of technology by regulators and industry with supportive guidance issued by the FDA
- ✓ Products have the potential to reduce drug development costs and time while improving success rates
- ✓ Steady growth in pharmaceutical industry R&D expenditures provides expanding target market
 - ~\$170B in 2020 growing around 3% per year³
- ✓ 10+ year track record of consistent revenue and profitability growth
 - Recent revenue CAGR of 20%+

Financial Summary and Selected Financial Information

Nasdaq Global Select Market	SLP
Q2 Cash and short-term investments	\$118M
Q2 Borrowed Debt Outstanding	\$0
Market Capitalization (a/o 5/12/21)	\$1.1B
Q2 Fully Diluted Shares Outstanding	20.8M
30-Day Avg. Daily Trading Volume (a/o 5/12/21)	~204K

Covering Analysts

Bank	Analyst
Craig-Hallum	Matt G. Hewitt
Oppenheimer & Co.	Francois Brisebois
Raymond James	Dane Leone

Q&A

Questions & Answers

Thank you!



Learn More! www.simulations-plus.com

References

1. *J Health Econ.* 2016 May;47:20-33.
2. Brochure: ["Biopharmaceutical Research & Development: The Process Behind New Medicines"](#). PhRMA.
3. EvaluatePharma® World Preview 2017, Outlook to 2022, 10th Edition, June 2017, p. 19.